ABSTRACT
Drug-induced lupus is a rare drug reaction featuring the same symptoms as idiopathic lupus erythematosus. Recently, with the introduction of new medicines in clinical practice, an increase in the number of illness-triggering implicated drugs has been reported, with special emphasis on anti-TNF-α drugs. In the up-to-date list, almost one hundred medications have been associated with the occurrence of drug-induced lupus. The authors present two case reports of the illness induced respectively by hydralazine and infliximab, addressing the clinical and laboratorial characteristics, diagnosis, and treatment.
Subject(s)
Antihypertensive Agents/adverse effects , Gastrointestinal Agents/adverse effects , Hydralazine/adverse effects , Infliximab/adverse effects , Lupus Erythematosus, Cutaneous/chemically induced , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Adult , Humans , Lupus Erythematosus, Cutaneous/pathology , Male , Middle Aged , Skin/pathologyABSTRACT
Drug-induced lupus is a rare drug reaction featuring the same symptoms as idiopathic lupus erythematosus. Recently, with the introduction of new medicines in clinical practice, an increase in the number of illness-triggering implicated drugs has been reported, with special emphasis on anti-TNF-α drugs. In the up-to-date list, almost one hundred medications have been associated with the occurrence of drug-induced lupus. The authors present two case reports of the illness induced respectively by hydralazine and infliximab, addressing the clinical and laboratorial characteristics, diagnosis, and treatment.
.Subject(s)
Adult , Humans , Male , Middle Aged , Antihypertensive Agents/adverse effects , Gastrointestinal Agents/adverse effects , Hydralazine/adverse effects , Infliximab/adverse effects , Lupus Erythematosus, Cutaneous/chemically induced , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Lupus Erythematosus, Cutaneous/pathology , Skin/pathologyABSTRACT
Relata-se o caso de paciente que sofreu infarto agudo do miocárdio após uso de anfepramona, um análogo da anfetamina. Discutem-se seus efeitos colaterais, mecanismos de lesão e risco - benefício no tratamento da obesidade em relação às doenças cardiovasculares. Conclui-se que o uso dessa droga deve ser feito com cautela e sempre sob orientação médica.